[1] |
荆可, 冯素英. 青斑血管炎的研究进展[J]. 中华皮肤科杂志, 2016,49(5):371⁃374. doi: 10.3760/cma.j.issn.0412⁃4030.2016. 05.021.
|
[2] |
袁建国, 蔡在胜, 刘睿, 等. 47例青斑血管炎临床分析[J]. 中华皮肤科杂志, 2013,46(9):630⁃632. doi: 10.3760/cma.j.issn. 0412⁃4030.2013.09.006.
|
[3] |
冯素英, 靳培英. 20例青斑血管炎患者的临床特点和治疗分析[J]. 中华皮肤科杂志, 2006,39(10):571⁃573. doi: 10.3760/j.issn:0412⁃4030.2006.10.006.
|
[4] |
Vasudevan B, Neema S, Verma R. Livedoid vasculopathy: a review of pathogenesis and principles of management[J]. Indian J Dermatol Venereol Leprol, 2016,82(5):478⁃488. doi: 10.4103/0378⁃6323.183635.
|
[5] |
Georgesen C, Fox LP, Harp J. Retiform purpura: workup and therapeutic considerations in select conditions[J]. J Am Acad Dermatol, 2020,82(4):799⁃816. doi: 10.1016/j.jaad.2019.07.113.
|
[6] |
Human A, Pagnoux C. Diagnosis and management of ADA2 deficient polyarteritis nodosa[J]. Int J Rheum Dis, 2019,22 Suppl 1:69⁃77. doi: 10.1111/1756⁃185X.13283.
|
[7] |
Vakili S, Zampella JG, Kwatra SG, et al. Lymphocytic thrombophilic arteritis: a review[J]. J Clin Rheumatol, 2019,25(3):147⁃152. doi: 10.1097/RHU.0000000000000846.
|
[8] |
Kelly RI, Wee E, Balta S, et al. Lymphocytic thrombophilic arteritis and cutaneous polyarteritis nodosa: clinicopathologic comparison with blinded histologic assessment[J]. J Am Acad Dermatol, 2020,83(2):501⁃508. doi: 10.1016/j.jaad.2019.10.068.
|
[9] |
Krueger S, McLean R, Amano S, et al. Primary livedoid vasculopathy associated with mononeuritis multiplex[J/OL]. Dermatol Online J, 2020,26(7):13030/qt4c80g04v. doi: 10.5070/ D3267049556.
|
[10] |
Corral Í, Kawiorski MM, Moreno C, et al. Vasculitic mononeuritis multiplex associated with livedoid vasculopathy[J]. Neurologia (Engl Ed), 2020,35(8):616⁃617. doi: 10.1016/j.nrl.2019.09.004.
|
[11] |
Gonzalez Santiago TM, Zavialov A, Saarela J, et al. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa[J]. JAMA Dermatol, 2015,151(11):1230⁃1234. doi: 10.1001/jamadermatol.2015.1635.
|
[12] |
Kendall JL, Springer JM. The many faces of a monogenic autoinflammatory disease: adenosine deaminase 2 deficiency[J]. Curr Rheumatol Rep, 2020,22(10):64. doi: 10.1007/s11926⁃020⁃00944⁃1.
|
[13] |
Lee JS, Cho S. Methylene tetrahydrofolate reductase C677T polymorphism in Korean livedoid vasculopathy patients[J]. J Am Acad Dermatol, 2021,84(4):1068⁃1069. doi: 10.1016/j.jaad. 2020.05.158.
|
[14] |
Marsch WC, Komatsuzaki S, Mueller A, et al. Livedoid vasculopathy: does hyperhomocysteinaemia play an aetiological role?[J]. Eur J Dermatol, 2019,29(3):287⁃293. doi: 10.1684/ejd.2019.3554.
|
[15] |
Deng A, Gocke CD, Hess J, et al. Livedoid vasculopathy associated with plasminogen activator inhibitor⁃1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator[J]. Arch Dermatol, 2006,142(11):1466⁃1469. doi: 10.1001/archderm.142.11.1466.
|